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Abstract
Background
Resistance to intravenous immunoglobulin (IVIG) occurs in 10–20% of patients with Kawa-
saki disease (KD). The risk of resistance is about two-fold higher in patients with elevated
gamma glutamyl transferase (GGT) levels. We sought to understand the biological mecha-
nisms underlying IVIG resistance in patients with elevated GGT levels.
Method
We explored the association between elevated GGT levels and IVIG-resistance with a cohort
of 686 KD patients (Cohort I). Gene expression data from 130 children with acute KD (Cohort
II) were analyzed using the R square statistic and false discovery analysis to identify genes
that were differentially represented in patients with elevated GGT levels with regard to IVIG
responsiveness. Two additional KD cohorts (Cohort III and IV) were used to test the hypothe-
sis that sialylation and GGT may be involved in IVIG resistance through neutrophil apoptosis.
Results
Thirty-six genes were identified that significantly explained the variations of both GGT
levels and IVIG responsiveness in KD patients. After Bonferroni correction, significant
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request. Requests for the data should be directed
to Drs. Burns and Lee as following: Clinical
associations with IVIG resistance persisted for 12 out of 36 genes among patients with ele-
vated GGT levels and none among patients with normal GGT levels. With the discovery of
ST6GALNAC3, a sialyltransferase, as the most differentially expressed gene, we hypothe-
sized that sialylation and GGT are involved in IVIG resistance through neutrophil apoptosis.
We then confirmed that in Cohort III and IV there was significantly less reduction in neutro-
phil count in IVIG non-responders.
Conclusions
Gene expression analyses combining molecular and clinical datasets support the hypothe-
ses that: (1) neutrophil apoptosis induced by IVIG may be a mechanism of action of IVIG in
KD; (2) changes in sialylation and GGT level in KD patients may contribute synergistically to
IVIG resistance through blocking IVIG-induced neutrophil apoptosis. These findings have
implications for understanding the mechanism of action in IVIG resistance, and possibly for
development of novel therapeutics.
Introduction
Kawasaki disease (KD) is an acute systemic vasculitis of infants and children, that occurs
world-wide [1], but the biology of this condition is not well understood. Coronary artery aneu-
rysms (CAA) occur in 25% of untreated patients, making KD the leading cause of acquired
heart disease in children [2, 3]. Therapy for KD includes high-dose aspirin and intravenous
immune globulin (IVIG) [4], which reduces the incidence of CAA to 5–7% when given within
the first 10 days of illness [5, 6]. However, 10%-20% of patients are resistant to IVIG [7, 8], and
are consequently at greater risk of developing CAA, and require additional adjunctive treat-
ments [5, 9]. We [10–12] and others [13–15] have found that serum gamma-glutamyl transfer-
ase (GGT) levels are elevated in the acute phase of KD patients and that higher GGT levels are
associated with IVIG resistance.
In this study, we explored the association of GGT level and IVIG resistance in KD patients
to try to understand the biological mechanism of action underlying these two clinical findings.
With our systematic analyses of gene regulation and associated clinical findings and outcomes,
we hypothesize: (1) neutrophil apoptosis induced by IVIG plays a pivotal role in IVIG re-
sponsiveness; (2) changes in sialylation and GGT levels in acute KD patients may contribute
together to IVIG resistance by blocking IVIG-induced neutrophil apoptosis.
Methods
The normal ranges of GGT and alanine aminotransferase (ALT) are shown in Table A in S1
File and Table B in S1 File respectively, while the normal range of C-reactive protein (CRP) is
shown in the footnotes of Table E in S1 File.
Cohort I: Subjects used to analyze the relationship between the levels of
GGT and IVIG resistance
A cohort with 686 subjects with KD (Cohort I) was used to explore the associations between
GGT levels and IVIG resistance. All subjects in this cohort were enrolled at Rady Children’s
Hospital in San Diego after obtaining written parental informed consent and patient assent as
appropriate. All subjects were treated with 2 g/kg of IVIG (Gammagard1) over a 10–12 hour
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period as per the pharmacy’s standard protocol. The study protocol was conducted in accor-
dance with the Declaration of Helsinki and was approved by Institutional Review Boards
of UCSD and Stanford University. KD subjects in this study were: a) patients with fever
(38.0˚C rectally or orally) for no more than 10 days, plus at least four of the five principal
clinical criteria, b) patients meeting fewer criteria but with coronary artery abnormalities
(CAA) (Z-score2.5 for left anterior descending [LAD] and/or right coronary arteries
[RCA]) documented by echocardiogram, and c) patients with fewer than 4 clinical criteria but
meeting the American Heart Association (AHA) criteria for incomplete KD by laboratory cri-
teria [4]. KD subjects meeting the inclusion criteria were identified from the database main-
tained at the UCSD KD Research Center. We obtained prospectively collected demographic
and clinical data, the results of laboratory studies prior to IVIG administration, and IVIG-
responsiveness. IVIG-resistance was defined as persistent or recurrent fever (rectal or oral
temperature38.0˚C) at least 36 hours but no longer than 7 days after completion of the initial
IVIG infusion (2g/kg) [10]. Subjects in this cohort were either treated with a second course of
IVIG or infliximab for IVIG-resistant KD.
Cohort II: Subjects used for gene expression profiling and GGT/IVIG
association analysis
We performed gene expression profiles of whole blood obtained from a sub-cohort of 146 KD
subjects (Cohort II) as previously described [16]. Of these KD subjects, 130 had complete data
on IVIG responsiveness and serum GGT levels available for subsequent analyses; clinical char-
acteristics of this cohort are summarized in Table C in S1 File. The odds ratios of gene expres-
sion stratified by IVIG response were calculated using logistic regression with glm2 in R [17].
For each of the 31,000 genes in the 130 subjects, the explained variations in GGT levels or
IVIG responsiveness were estimated using R square of linear regression or the McFadden’s
pseudo- R square [18, 19] of logistic regression [17], respectively.
Correction for multiple hypothesis testing on the explained variations was performed using
the permutation-based false discovery rate (FDR) analytical method [20]. FDRs of GGT- and
IVIG-associated variations for each gene were estimated using Monte Carlo simulation. Genes
with FDRs less than a threshold of 0.01 were considered true discoveries explaining the varia-
tions in GGT levels and IVIG responsiveness. The common genes among true discoveries of
both GGT and IVIG were used for the next analysis (Fig 1, Panel 2).
The study population was divided into two sub-cohorts, one with normal and the other
with elevated GGT levels, using age-specific reference ranges established in our clinical labora-
tory (Table A in S1 File). Logistic regression was performed for each of the 36 common genes
with FDR<1%, to evaluate its contribution to the risk for IVIG resistance in each sub-cohort.
The Bonferroni method was applied to correct for multiple hypothesis testing [21, 22].
Cohorts III and IV: Subjects used to investigate and validate the changes
of neutrophils in response to IVIG treatment
Cohort III was derived from the placebo arm of a phase 3, randomized, double-blind, placebo-
controlled trial of IVIG with or without infliximab for treatment of KD, which was conducted
from March 2009 to August 2012 in two children’s hospitals in the USA [23]. Cohort III
included 95 KD patients of the 98 KD patients from the placebo arm, and was used to investi-
gate changes of neutrophils in response to IVIG treatment. The 3 excluded placebo subjects
had missing data for IVIG response (n = 1) or absolute neutrophil count (n = 2). The study
protocol was reviewed and approved by the Institutional Review Boards at the University of
California San Diego’s and Nationwide Children’s Hospital. Written informed consent was
Significant Gene Expression Analysis of GGT-Associated IVIG Resistance
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obtained from the parents or legal guardians and assent, when appropriate, was obtained from
the patient.
To validate our observations on changes of neutrophils in response to IVIG treatment in
Cohort III, we utilized another independent cohort (Cohort IV) with 587 KD subjects.
Approved by the institutional review board of Korean University Medical Center, the medical
records of KD patients from January 2008 to December 2013 were reviewed. The diagnosis
and treatment of KD was based on AHA criteria [4]. CAA were diagnosed on the basis of the
criteria proposed by the Japanese Kawasaki Disease Research Committee in 1984 [24]. Patients
with complete differential leukocyte counts at diagnosis and 2 days after IVIG treatment, IVIG
response and CAA data were included. Detailed characteristics, clinical data and results of lab-
oratory studies of subjects were previously described [25].
Fig 1. Study outline of analyses to uncover unique gene expression patterns underlying IVIG responsiveness in subjects with elevated serum
GGT levels. (1) Analysis of GGT levels with IVIG responsive-ness; (2) Global gene expression analysis by R2 statistic and FDR anal-yses to identify genes,
explaining variations in both IVIG responsiveness and GGT elevation; (3) Targeted analysis of the step 2 discovered genes in either GGT normal or elevated
subgroups to reveal gene expression patterns specific for each sub-group of subjects; (4) Pathway and literature analysis to explore the underlying biology of
IVIG resistance in subjects with GGT elevation.
doi:10.1371/journal.pone.0167434.g001
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The absolute neutrophil count (ANC) (mature and immature (band) forms) were calcu-
lated for both the UCSD and Korean cohorts.
General data analysis
All statistical analyses and plots were performed using R 3.2.2 [26] and ggplot2 [27] if not men-
tioned explicitly. The difference in neutrophil reduction between the IVIG responders and the
IVIG non-responders after treatment was tested with the Mann-Whitney U-test. The scatter
plot curve of neutrophil reduction versus ANC was done with loess fit.
Results
Association between IVIG resistance risk and GGT levels
The 575 IVIG responders and 111 IVIG non-responders in Cohort I had similar demographic
and clinical characteristics (Table 1). Subjects were treated with IVIG just after obtaining base-
line laboratory values. In addition to elevated GGT levels, IVIG resistant subjects also had sig-
nificantly higher ALT, CRP values, band percentage, and absolute white blood cell count. This
Table 1. Clinical and laboratory characteristics values of 686 IVIG responsive and resistant KD subjects.
IVIG responders (N = 575) IVIG non-responders (N = 111) P value
Age at diagnosis, years 2.6 (1.4–4.3) 2.4 (1.4–4.2) NS
Male, N (%) 350 (60.9) 72 (64.9) NS
Illness day at sample collection days 6 (5–7) 5 (4–6) NS
Incomplete KD, N (%) 67 (11.7) 9 (8.1) NS
Coronary artery aneurysms, N (%) 12 (2.1) 5 (4.5) NS
Ethnicity, N (%)
Asian 99 (17.2) 14 (12.6) NS
African-American 23 (4.0) 4 (3.6) NS
Caucasian 135 (23.5) 30 (27.0) NS
Hispanic 186 (32.3) 37 (33.3) NS
More than race 111 (19.3) 24 (21.6) NS
Other 8 (1.3) 1 (0.9) NS
CRP, mg/dL 7.0 (4.0–14.6) 8.3 (5.2–18.6) < 0.01
ESR, mm/h 61 (42–77) 53 (36–68) < 0.05
WBC, ×103/mm3 13.2 (10.6–17.3) 13.6 (10.6–17.4) NS
ANC, cells/mm3 8,836 (6,440–11,696) 9,585 (7,301–12,328) NS
ZHgb -1.2 (-2.1–0.42) -1.2 (-2.2–0) NS
ALT, IU/L 35 (19–98) 76 (38–142) < 0.001
GGT, IU/L 37 (17–109) 76 (28–157) < 0.001
Albumin, g/dL 3.9 (3.5–4.2) 3.7 (3.4–4.0) NS
Polymorphonuclear leukocytes (%) 54 (42–64) 51.0 (40.0–62.5) NS
Platelet count, ×103/mm3 373 (291–467) 340 (282–430) NS
Bands (%) 11.0 (4.0–19.0) 18.0 (10.0–32.2) < 0.001
ABC 1,440 (554–2,634) 2,450 (1,272–4,512) < 0.001
Values are presented as median (IQR: Interquartile range). KD: Kawasaki disease, IVIG: intravenous immunoglobulin, CRP: C-reactive protein, ESR:
erythrocyte sedimentation rate, WBC: white blood count, ANC: absolute neutrophil count, ZHgb: standard deviations from the mean hemoglobin
concentration normalized for age, ALT: alanine aminotransferase, GGT: gamma-glutamyl transferase. The difference between groups were tested using
Wilcoxon rank sum test, NS: not significant.
doi:10.1371/journal.pone.0167434.t001
Significant Gene Expression Analysis of GGT-Associated IVIG Resistance
PLOS ONE | DOI:10.1371/journal.pone.0167434 December 21, 2016 5 / 15
is in line with previous meta-analysis [15] that serum levels of ALT and GGT in IVIG non-
responders were significantly higher than that in the IVIG responders.
IVIG resistance was examined according to GGT levels quintiles (Fig 2). IVIG resistance
risk in each quintile exhibited a progressive association with the GGT levels and the odds ratio
reached 2.6 for subjects in the highest quintile compared with the lowest quintile.
Global gene expression analyses with FDR
Of the 130 KD subjects with gene expression data in Cohort II, 100 were IVIG responders and
30 were IVIG non-responders. At the time of diagnosis, 45 subjects had normal serum GGT
levels, and 85 had elevated GGT levels (Table C in S1 File). In multiple hypothesis testing of
Fig 2. Odds ratio for IVIG resistance per quintile of GGT level. The odds ratios were calculated against the first quintile with the lowest GGT level. The
95% confidential intervals were shown as the error bars. **: P value < 0.01 using fisher exact test.
doi:10.1371/journal.pone.0167434.g002
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gene expression for GGT levels and IVIG resistance, the number of true discovered genes
decreased with increasing R square values (Fig 3). The median of false discoveries decreased
much faster than the total number of discoveries because the event, that a gene can explain the
significant variations of the randomized response, can only occur by chance. In analyses of
IVIG resistance and elevated GGT levels, the R square thresholds corresponding to a TDR of
99% resulted in discovery of 837 and 613 genes, respectively. Of these, 36 were common to
both gene sets (Fig 3 bottom panel).
Candidate gene analysis with normal and elevated GGT level sub-cohorts
In order to explore these 36 genes with regard to the GGT-level-associated IVIG responses, we
partitioned Cohort II into sub-cohorts with normal (45 subjects including 38 IVIG responders
and 7 non-responders) or elevated GGT levels (85 subjects including 62 IVIG responders
and 23 non-responders). After applying the Bonferroni correction, significant associations
(P value < 0.05) with IVIG resistance persisted for 12 out of the 36 genes among patients with
elevated GGT levels and none among patients with normal GGT levels (Table 2). The highest
Fig 3. R2 statistic and FDR analyses with respect to GGT levels and IVIG responsiveness. Top left panel: discovery of genes explaining variations in
IVIG responsiveness. Top right panel: discovery of genes explaining variations in GGT levels. Bottom panel: Venn diagram analysis uncovering genes
explaining variations in both IVIG responsiveness and GGT levels.
doi:10.1371/journal.pone.0167434.g003
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odds ratio was 114.1 for ST6GALNAC3 in the GGT-elevated subgroup, and exhibited about a
50-fold difference between the subgroups (Table 2).
Association of the reduced ANC with IVIG treatment outcomes
As shown in Fig 4A, 10 of 95 subjects in Cohort III are IVIG non-responders. Reduction of
neutrophil counts after IVIG treatment were common among both IVIG responders (92%)
and IVIG non-responders (60%). IVIG non-responders had significantly lower (P value
9.6 × 10−3) percentage reduction in neutrophil count than responders. A similar pattern was
observed in Cohort IV, which included 222 IVIG non-responders and 365 IVIG responders
(Fig 4B, P value 1.4 × 10−13). We further delineated changes in ANC by stratifying patients
into quintiles according to the ANC at presentation (S1 Fig). In comparison with non-
responders, a significantly greater decline in ANC was observed in responders in every quintile
(S1 Fig). The ANC increased in a small fraction of patients in both groups after IVIG treat-
ment: 14.4% of non-responders and 3.5% of responders. We plotted the trending curve of
either absolute or percentage of neutrophil reduction against the pretreatment ANC (Cohort
III subjects, S2A and S2B Fig; Cohort IV subjects, S2C and S2D Fig). This trending curve
showed that neutrophil reduction increased as a function of the pretreatment ANC in both the
resistant and responsive subgroups. Thus, Cohort IV analysis validated the Cohort III observa-
tions that the IVIG non-responders have less reduction in neutrophil count than the IVIG
responders. Within subgroup with elevated GGT levels (S3 Fig), the association between high
levels of GGT and neutrophil reduction revealed no clear trend.
Discussion
Our study highlights the significant association of the elevated GGT levels with IVIG treatment
outcomes in KD patients. Global gene expression analysis revealed 36 genes that could explain
Table 2. List of 12 genes significantly contributing to IVIG resistance in subgroup with elevated GGT levels identified by logistic regression from
36 genes found by R2 statistic and FDR analyses.
Gene symbol HGNC name Normal GGT Elevated GGT
Odds ratio
(95% CI)
P
value*
Odds ratio
(95% CI)
P
value*
ST6GALNAC3 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 3
2.3 (0.003–
2217)
114.1 (9.2–
2540)
0.03
LAMTOR5 late endosomal/lysosomal adaptor, MAPK and MTOR activator 5 2.1 (0.3–177.7) 112.5 (10–2034) 0.02
CMTM4 CKLF-like MARVEL transmembrane domain containing 4 0.7 (0.01–23.1) 34.7 (5.5–
303.1)
0.02
LOC653907 similar to complement component (3b/4b) receptor 1 isoform F precursor
(obsolete)
1.2 (0.1–16.5) 19.4 (4.1–
119.2)
0.02
TSHZ3 teashirt zinc finger homeobox 3 1.1 (0.2–10.4) > 0.01 14.6 (3.7–72.9) 0.01
GADD45A growth arrest and DNA-damage-inducible, alpha 0.3 (0.04–1.8) 12.2 (4.0–49.4) 0.003
DACH1 dachshund family transcription factor 1 0.4 (0.04–3.4) 8.8 (2.9–35.0) 0.02
PCOLCE2 procollagen C-endopeptidase enhancer 2 1.2 (0.2–6.4) 4.4 (1.9–11.3) 0.04
MMP8 matrix metallopeptidase 8 1.2 (0.2–5.2) 2.8 (1.7–5.2) 0.01
ATP8B2 ATPase, aminophospholipid transporter, class I, type 8B, member 2 0.1 (0.005–2.5) 0.1 (0.02–0.4) 0.05
ABCF1 ATP-binding cassette, sub-family F (GCN20), member 1 0.2 (0.002–
12.0)
0.02 (0.0007–
0.2)
0.05
SSBP3 single stranded DNA binding protein 3 0.03 (0.0003–
1.6)
0.03 (0.0003–
0.1)
0.01
* P values adjusted by Bonferroni correction.
doi:10.1371/journal.pone.0167434.t002
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the variations of both IVIG treatment outcomes and GGT levels in acute KD patients. Of these
36 genes, 12 retained an association with IVIG resistance in the subgroup with elevated GGT
levels, while none remained significant in the normal GGT subgroup. In comparison, although
both ALT and GGT levels in IVIG resistant patients were significantly higher than that in the
IVIG responsive group, none of the 12 GGT-associated genes were significantly associated
with IVIG responses in either the normal or elevated ALT subgroups (Table D in S1 File).
These observations suggest that a unique gene expression pattern exists in KD subjects with
elevated GGT levels, which may account for their higher risk of resistance to IVIG treatment.
Molecular and immunological markers have been shown to segregate and predict respond-
ers and non-responders to IVIG therapy [28]. Consistent with previous observations of signifi-
cantly elevated neutrophil counts in IVIG-nonresponsive patients, the circulating levels of
inflammatory mediators including granulocyte-colony stimulating factor (G-CSF) were signif-
icantly higher in IVIG non-responders [29] and were positively correlated with higher levels of
matrix metalloproteinase-8 (MMP-8), which is 1 of the 12 GGT associated genes found in this
Fig 4. Neutrophil reduction in response to IVIG treatment in two independent cohorts. All P values
were calculated using Wilcoxon rank sum test. A) Cohort III. B) Cohort IV. The number of patients with rising
neutrophil counts after IVIG treatment were indicated by the numbers below x axis alongside each box plot.
The P values were calculated using Wilcoxon rank sum test.
doi:10.1371/journal.pone.0167434.g004
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study [29, 30]. We reasoned that the 12 GGT associated differentially expressed genes were
novel, and may provide molecular insight on the IVIG response. We focused the analyses on
ST6GALNAC3, which was found to have the highest odds ratio in the elevated GGT group and
about a 50-fold greater risk compared to the normal GGT group. ST6GALNAC3 is a sialyltrans-
ferase that exclusively utilizes α2, 3-sialylated ganglioside GM1b as a donor to synthesize ganglio-
side GD1α by adding a α2, 6-sialic acid onto β-galactoside [31]. The branching α2, 6-sialic acid,
could potentially increase the binding affinity of GD1α to siglec-9, a sialic acid-binding immuno-
globulin-type lectin which preferably binds to α 2,3- and α 2,6-sialyl residues [32] on monocytes
and neutrophils [33] (Fig 5). We observed that the ANC declined in response to IVIG in both
IVIG responders and non-responders (Fig 4B). Given that IVIG non-responders are still febrile
with ongoing inflammation, we hypothesized a direct impact of IVIG on neutrophils instead of a
secondary therapeutic effect of global inflammation reduction. This is consistent with previous
smaller cohort observations [34, 35]. Neutrophils isolated from IVIG responders exhibit acceler-
ated spontaneous apoptosis in vitro [36], suggesting that apoptosis may cause the reduction of
neutrophils during IVIG treatment. Conversely, neutrophils isolated from IVIG non-responders
were less inclined to undergo apoptosis in vitro [36]. These observations are in line with our
hypothesis that neutrophils in non-responders may be more resistant to IVIG induced apoptosis.
In addition, neutrophil count was used as one of the clinical features for IVIG resistance score
[37]. Circulating neutrophils and their over activation maybe one of the underlying progressive
indicators in IVIG resistance and the severity of the heart lesion [38, 39].
Despite the fact there have been reports of KD occurring in the presence of Autoimmune
neutropenia (AIN)[40, 41], for the majority of KD patients, the neutrophil count is elevated.
We showed that IVIG non-responders had significantly lower percentage reduction in neutro-
phil count than responders. The observation of KD symptoms[41] with neutropenia suggested
that there might be two KD subgroups with different underlying mechanisms of pathophysiol-
ogy involving neutrophils. We hypothesize that, within a small subgroup of KD, neutrophil
may not necessarily be involved in the pathogenesis and manifestation of KD but rather in the
progression and severity of coronary artery lesions (CAL). One explanation in the AIN case
with KD is that the neutrophil count sampled in peripheral blood does not always reflect the
neutrophil count in the marginated pool or in the tissues. Autopsy data clearly show that neu-
trophils are the “first responders” in the tissues. Before they can enter the arterial wall, they
must marginate. Neither the marginated pool nor the tissue infiltrating neutrophils are mea-
sured when blood is drawn. Therefore, it is possible, in the minor subgroup of AIN with KD,
neutrophils may still be central to the pathophysiology of the disease even though the numbers
measured in the flowing portion of the peripheral blood is low.
Naturally occurring antibodies (Nabs) against siglec-9 (Nabs-siglec-9) are found in IVIG
and can induce apoptosis in neutrophils [42–44]. Moreover, this apoptosis is accelerated by
proinflammatory cytokines. Granulocyte/macrophage colony-stimulating factor (GM-CSF)
and interferon-γ (IFN- γ), which are often upregulated in KD [45, 46]. Therefore, we postulate
that Nabs-siglec-9 in IVIG can induce neutrophil apoptosis in KD, explaining the association
between the neutrophil reduction and therapeutic outcomes of IVIG (Fig 5): (1) the high
expression level of ST6GALNAC3 leads to increased enzymatic activity of ST6GALNAC3, pro-
ducing more GD1α, which in turn binds to siglec-9 and prevents its recognition by Nabs-
siglec-9 in IVIG; (2) elevation of GGT levels will increase the degradation of extracellular glu-
tathione (GSH) to provide cysteine for de novo synthesis of intracellular GSH, reducing the
intracellular reactive oxygen species (ROS) in neutrophils. Reduction of ROS in neutrophils
decreases neutrophil apoptosis induced by IVIG in the presence of GM-CSF and IFN- γ [44].
However, IVIG works through a myriad of paths. Neutrophil apoptosis is probably one of
MANY mechanisms by which IVIG may reduce inflammation.
Significant Gene Expression Analysis of GGT-Associated IVIG Resistance
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Conclusions
To the best of our knowledge, we are the first to integrate multifaceted data sets of expression
profiles, clinical parameters and outcomes to explore KD pathophysiology. We demonstrated
that KD subjects with elevated GGT levels have a unique gene expression pattern that overlaps
with the gene expression pattern associated with IVIG resistance. Our study suggests that
reduction of circulating neutrophils is one of the hallmarks of the therapeutic effects of IVIG.
Neutrophil activation and intracellular ROS effect due to elevated GGT levels may not be
directly associated with KD susceptibility but be mechanistically critical in IVIG resistance
and heart lesion pathogenesis [38, 39, 47]. Therefore, both increased ST6GALNAC3 and ele-
vated GGT levels may lead to reduced neutrophil apoptosis, and consequently IVIG resistance
(Fig 5).
Fig 5. Hypothesis of the underlying biology of IVIG responsiveness involving neutrophils, siglec-9, ST6GALNAC3, and GGT.
doi:10.1371/journal.pone.0167434.g005
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We propose two future testable hypotheses: (1) Nabs against siglec-9 (Nabs-siglec-9) in
IVIG can induce apoptosis in neutrophils and contribute to the efficacy of IVIG in the treat-
ment of KD. (2) Increased sialylation of gangliosides block IVIG-mediated neutrophil apopto-
sis and lead to persistent inflammation and IVIG resistance.
If confirmed, our findings may account for the variable effectiveness of different IVIG lot
preparations [48, 49], potentially allowing a new quality control approach. Monoclonal anti-
bodies against Siglec-3 and Siglec-2 are in clinical trials [50]. If developed, therapies to induce
neutrophil apoptosis could be a more effective KD treatment.
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